<DOC>
	<DOCNO>NCT01393821</DOCNO>
	<brief_summary>This clinical trial study menadione topical lotion treat skin discomfort psychological distress patient cancer receive panitumumab , erlotinib hydrochloride , cetuximab . Menadione topical lotion may prevent rash skin discomfort help alleviate psychological distress pain patient receive treatment panitumumab , erlotinib hydrochloride , cetuximab</brief_summary>
	<brief_title>Menadione Topical Lotion Treating Skin Discomfort Psychological Distress Patients With Cancer Receiving Panitumumab , Erlotinib Hydrochloride , Cetuximab</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Explore effectiveness menadione topical lotion face prevent cutaneous psychological discomfort epidermal growth factor receptor ( EGFR ) inhibitor . SECONDARY OBJECTIVES : I . Explore adverse event profile menadione topical lotion face prevent rash EGFR inhibitor . II . Explore whether rash adverse event worsen 4 week period 4-week intervention . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients apply menadione topical lotion twice daily ( BID ) 28 day . ARM II : Patients apply topical placebo lotion BID 28 day . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Vitamin K 3</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<criteria>Age 18 year old . Patient schedule start epidermal growth factor receptor inhibitor ( must one three : panitumumab , erlotinib , cetuximab ) within next 3 day patient already start epidermal growth factor receptor inhibitor longer 3 day sign symptom potentially suggestive EGFR inhibitor toxicity . Ability reliably apply Menadione Topical Lotion / placebo twice day face . Ability complete questionnaire ( ) assistance . Negative pregnancy test ( serum urine ) do â‰¤ 7 day prior registration , woman childbearing potential . Willing photograph take assess rash . Any active facial and/or chest rash , include adult acne , time randomization . Cutaneous metastasis , skin cancer , history precancerous skin lesion involve face and/or chest . Use topical corticosteroid face and/or chest time study entry anticipate use next 8 week . Any type ongoing therapy rash . Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception since study involve agent know genotoxic , mutagenic teratogenic effect Use antibiotic time study anticipate use 8 week immediately follow study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>